Navigation Links
Quark Pharmaceuticals to Participate in IBC's Oligonucleotide Therapeutics: From Concept to Implementation Conference
Date:8/3/2009

p>Daniel Zurr, Ph.D., President and Chief Executive Officer of Quark, said, "Dr. Thompson's active and visible roles at the conference represent Quark's leadership position in the RNAi industry as the pioneer in systemic siRNA administration. We are at the forefront in oligonucleotide therapeutic development and look forward to discussing practical strategies and forward-looking approaches to support the current momentum in research and development in the field."

Dr. Thompson has been a leader in siRNA development for several years. Prior to joining Quark, he was Director of Research and Development at Genta, and previously Director of Biology Research at Sirna Therapeutics (formerly named Ribozyme Pharmaceuticals), which was acquired by Merck.

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel RNAi-based therapeutics. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's RNAi technology includes novel siRNA structures and chemistry providing Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability for non-invasive delivery of siRNA to other target tissues including the eye, ear, lung, spinal cord and brain.

PF-4523655 (RTP801i-14), currently in Phase II clinical trials, is a synthetic, chemically modified siRNA designed to inhibit the expression of the gene RTP801 discovered by Quark through the gene discovery platform BiFAR. PF-4523655 is licensed to Pfizer. In addition, Quark's current clinical pipeline includes QPI-1002, the first systemically administered siRNA drug in human clinical trials, developed by Quark for the prevention of acute kidney injury (AKI) following major cardiovascular surgery and the prophylaxis of delayed graft function after kidney transplantation
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Quark Pharmaceuticals Announces Data Indicating Potential Utility of QPI-1007 for Treatment of Glaucoma
2. Quark Pharmaceuticals Announces the Presentation of Data Indicating Potential Utility of QPI-1002 in Chronic Kidney Disease at the RNA Interference Summit
3. Quark Pharmaceuticals Presents Data on Synthetic siRNAs for Prevention of Ocular and Inner Ear Sensory Cell Damage
4. Quark Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference
5. Quark Pharmaceuticals Receives FDA Approval of IND for Kidney Transplant siRNA Drug DGFi
6. Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma
7. MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results
8. Savient Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for KRYSTEXXA(TM)
9. Transcept Pharmaceuticals to Hold Conference Call on Agreement with Purdue Pharmaceutical Products L.P. to Commercialize Intermezzo(R) in the United States
10. Excaliard Pharmaceuticals Appoints Jay Birnbaum, Ph.D. to the Board of Directors.
11. Arena Pharmaceuticals to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2015)... Philadelphia, Pennslyvania (PRWEB) April 19, 2015 ... and proved tolerable in a small group of healthy ... (UPCI), partner with UPMC CancerCenter , announced ... (AACR) Annual Meeting in Philadelphia. , The ... clinical trial, which will recruit participants at high risk ...
(Date:4/19/2015)... 2015 New court documents issued by ... that Lipitor lawsuits ( http://www.lipitorlawsuitcenter.com/ ) continue to mount ... District of South Carolina. According to the April 15th ... in the proceeding on behalf of individuals who allegedly ... the cholesterol-lowering statin. This represents an increase of 110 ...
(Date:4/19/2015)... April 19, 2015 Family and friends of ... Brains in Memory of Brad Baddeley event to honor ... Foundation. , Bowling for Brains is cheduled to take place ... Dudley Street in Lincoln, Nebraska. Participants may arrive at 12:30pm ... 3:00pm. , The cost is only $4 per game and ...
(Date:4/18/2015)... (PRWEB) April 18, 2015 Carinsurancequotesinfo.com has ... insurance can cover physical injuries caused by a ... excellent financial coverage for a vehicle. A policy can ... by an accident. Drivers should always carry appropriate coverage ... insurance policy can be bought with several important riders ...
(Date:4/18/2015)... 2015 Review of Ophthalmology magazine and ... for Success’ program for cataract surgeons attending the American ... Diego, where eye surgeon Jeffrey L. Martin, MD will ... Dr. Martin is the Managing Partner of North Shore ... Dr. Martin to lead this year’s discussion on the ...
Breaking Medicine News(10 mins):Health News:Preventing Cancer with Broccoli Sprout Extract 2Health News:Preventing Cancer with Broccoli Sprout Extract 3Health News:Lipitor Lawsuits Mount, as New Court Report Shows More Than 100 Filings Added to Federal Litigation Since March 2Health News:Lipitor Lawsuits Mount, as New Court Report Shows More Than 100 Filings Added to Federal Litigation Since March 3Health News:Lincoln, NE’s Bowling for Brains to benefit Renowned Brain Aneurysm Foundation 2Health News:Lincoln, NE’s Bowling for Brains to benefit Renowned Brain Aneurysm Foundation 3Health News:Auto Insurance Plans Can Cover Physical Injuries Caused By An Accident! 2Health News:Dr. Jeffrey Martin Invited to Share Latest Breakthroughs in Cataract Care During Roundtable Discussion at National 2015 ASCRS Meeting In San Diego 2
... have poor functioning of a key heart measure may ... arteries.// ,The researchers looked specifically at how the ... the arteries, called endothelial functioning, affects the development of ... followed from childhood. Over the 21 years of the ...
... Prostate cancer is the most common cancer among men, affecting ... 220,000 new cases // of the disease are diagnosed every ... year. ,New research shows men who are diagnosed with ... a high risk of developing prostate cancer within one year. ...
... red wine each day could keep keep lung cancer away ... cancer and 187 patients requiring routine surgery between 1999 and ... early 60s. Patients were asked about their diet, smoking habits, ... each day. They were asked to specify if they drank ...
... New research shows that sleep disorders may be linked ... ADD ), // neuromuscular conditions, and psychiatric problems. ... patients with sleep apnea also had ADD. Results also ... insomnia. Further testing showed some of these patients also ...
... with uncontrolled asthma may be able to gain complete ... ,Researchers studied 3,416 patients with uncontrolled asthma. Some ... steroid for their asthma; some were on a low-dose ... steroid. Patients in all three subgroups were randomly assigned ...
... reduction surgery can successfully treat metabolic syndrome in most ... is a combination of conditions putting people at high ... is characterized by higher than normal blood sugar, high ... involved 645 patients who were treated for obesity with ...
Cached Medicine News:
(Date:4/17/2015)... Nonin Medical, a global leader in noninvasive medical monitoring, ... Steve Bucholz will retire May 1. Company founder ... Chief Executive Officer. In addition, Mr. Isaacson will continue ... transition to David Noel , Chief Financial Officer. ... to Nonin Medical,s growth," Mr. Isaacson said. "Under Steve,s ...
(Date:4/17/2015)... R.I , April 17, 2015 CVS ... a conference call on Friday, May 1, 2015, at ... its first quarter financial results. An audio ... through the Investor Relations portion of the CVS Health ... visit http://investors.cvshealth.com . This webcast will be archived ...
(Date:4/17/2015)... ASSESS shows   plasma circulating tumour DNA (ctDNA) ... tumour biopsy   IGNITE supports value of ... AstraZeneca today presented results from two key studies ... for epidermal growth factor receptor (EGFR) mutation status in newly ... clinical practice. [ 1 ] , ...
Breaking Medicine Technology:Nonin Medical's Philip Isaacson Expands CEO Role; President and COO Steve Bucholz to Retire May 1 2"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 2"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 3"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 4
... AUG. 2 Two major studies,published today in The ... pregnant women at risk for preterm delivery who can ... today. In one large multi-center trial led by ... whom had no prior history of preterm birth) who,received ...
... Population of Glioblastoma Patients Expected to Support ... Promising New Approach -, TUSTIN, Calif., Aug. 2 ... stage biopharmaceutical,company developing targeted monoclonal antibodies for the treatment ... the first,patient has been administered Cotara(R) in a new ...
Cached Medicine Technology:Progesterone Therapy and Preterm Birth: More Evidence Helps Identify Women Who Can Benefit 2Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India 2Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India 3Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India 4
Malaria device / strip (3 line, PAN-pLDH, P.f.-HRP2)...
High sensitive, specific one step immunochromatographic assay for human infectious disease...
High sensitive, specific one step immunochromatographic assay for human infectious disease...
Detection of Malarial antigen in Human whole blood....
Medicine Products: